1 min read
Add as a preferred source on GoogleBioNTech to Evaluate Pumitamig With Gilead’s Trodelvy
The companies are examining the combination as an initial treatment for triple-negative breast cancer with low or absent PD-L1 expression.
BioNTech will evaluate pumitamig alongside Gilead Sciences’ Trodelvy as an initial treatment option for patients with triple-negative breast cancer and low or absent PD-L1 expression. BioNTech announced the collaboration Thursday.
John Kim
John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.